FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2006808462> ?p ?o ?g. }

• W2006808462 endingPage "296" @default.
• W2006808462 startingPage "289" @default.
• W2006808462 abstract "Aims To determine the maximum tolerated dose, the recommended dose (RD) for phase II studies, dose-limiting toxicities and pharmacokinetics (PK) for plitidepsin administered as a 3-h intravenous infusion every 2 weeks (one cycle) to children with refractory or relapsed solid tumours. Methods Consecutive cohorts of patients were treated according to a standard ‘3 + 3’ design with escalating doses of plitidepsin at 4, 5 and 6 mg/m2. Additional 15 patients were recruited at the RD to further evaluate safety and pharmacokinetic associations with respect to age, dose level and toxicity. Results Thirty-eight of 41 patients registered received plitidepsin. Dose-limiting toxicities during the first three treatment cycles related to myalgia, elevated creatine phosphokinase, transaminase increase and nausea/vomiting. The RD for plitidepsin is 5 mg/m2. PK analyses revealed high inter-patient variability in plasma, but a similar clearance of plitidepsin in children and adolescents. One partial response confirmed at 4 weeks in a patient with neuroblastoma and one unconfirmed partial response in a pancreatoblastoma were observed; four other patients with neuroblastoma, medulloblastoma, glioblastoma and rhabdoid tumour had disease stabilisations lasting ⩾3 months. Conclusion Plitidepsin administered to children as a 3-h infusion every 2 weeks is received with manageable toxicity for children with cancer, and the RD is 5 mg/m2. Pharmacokinetic parameters in children and adolescents are comparable to adults. Future phase II studies of plitidepsin are warranted, and our results suggest that plitidepsin could be appropriately developed in combination with other antitumour where myelosuppression is dose-limiting." @default.
• W2006808462 created "2016-06-24" @default.
• W2006808462 creator A5003501318 @default.
• W2006808462 creator A5004458586 @default.
• W2006808462 creator A5007422243 @default.
• W2006808462 creator A5007564466 @default.
• W2006808462 creator A5014379184 @default.
• W2006808462 creator A5037515069 @default.
• W2006808462 creator A5051922909 @default.
• W2006808462 creator A5054755553 @default.
• W2006808462 creator A5067202962 @default.
• W2006808462 creator A5070615752 @default.
• W2006808462 creator A5079336589 @default.
• W2006808462 creator A5090194957 @default.
• W2006808462 date "2012-02-01" @default.
• W2006808462 modified "2023-10-14" @default.
• W2006808462 title "A phase I and pharmacokinetic study of plitidepsin in children with advanced solid tumours: An Innovative Therapies for Children with Cancer (ITCC) study" @default.
• W2006808462 cites W1880913164 @default.
• W2006808462 cites W1964234385 @default.
• W2006808462 cites W1964356886 @default.
• W2006808462 cites W1967032202 @default.
• W2006808462 cites W1970304552 @default.
• W2006808462 cites W1976843162 @default.
• W2006808462 cites W1983939149 @default.
• W2006808462 cites W2009096079 @default.
• W2006808462 cites W2017980890 @default.
• W2006808462 cites W2040661351 @default.
• W2006808462 cites W2043450431 @default.
• W2006808462 cites W2044295936 @default.
• W2006808462 cites W2050662664 @default.
• W2006808462 cites W2103409514 @default.
• W2006808462 cites W2106708030 @default.
• W2006808462 cites W2122430929 @default.
• W2006808462 cites W2125540170 @default.
• W2006808462 cites W2130030010 @default.
• W2006808462 cites W2138349159 @default.
• W2006808462 cites W2141816218 @default.
• W2006808462 cites W2152642419 @default.
• W2006808462 cites W2156792347 @default.
• W2006808462 cites W2163188114 @default.
• W2006808462 cites W2167805334 @default.
• W2006808462 cites W2227444605 @default.
• W2006808462 doi "https://doi.org/10.1016/j.ejca.2011.10.036" @default.
• W2006808462 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22119199" @default.
• W2006808462 hasPublicationYear "2012" @default.
• W2006808462 type Work @default.
• W2006808462 sameAs 2006808462 @default.
• W2006808462 citedByCount "30" @default.
• W2006808462 countsByYear W20068084622013 @default.
• W2006808462 countsByYear W20068084622014 @default.
• W2006808462 countsByYear W20068084622015 @default.
• W2006808462 countsByYear W20068084622017 @default.
• W2006808462 countsByYear W20068084622018 @default.
• W2006808462 countsByYear W20068084622019 @default.
• W2006808462 countsByYear W20068084622020 @default.
• W2006808462 countsByYear W20068084622021 @default.
• W2006808462 countsByYear W20068084622022 @default.
• W2006808462 crossrefType "journal-article" @default.
• W2006808462 hasAuthorship W2006808462A5003501318 @default.
• W2006808462 hasAuthorship W2006808462A5004458586 @default.
• W2006808462 hasAuthorship W2006808462A5007422243 @default.
• W2006808462 hasAuthorship W2006808462A5007564466 @default.
• W2006808462 hasAuthorship W2006808462A5014379184 @default.
• W2006808462 hasAuthorship W2006808462A5037515069 @default.
• W2006808462 hasAuthorship W2006808462A5051922909 @default.
• W2006808462 hasAuthorship W2006808462A5054755553 @default.
• W2006808462 hasAuthorship W2006808462A5067202962 @default.
• W2006808462 hasAuthorship W2006808462A5070615752 @default.
• W2006808462 hasAuthorship W2006808462A5079336589 @default.
• W2006808462 hasAuthorship W2006808462A5090194957 @default.
• W2006808462 hasConcept C112705442 @default.
• W2006808462 hasConcept C121608353 @default.
• W2006808462 hasConcept C126322002 @default.
• W2006808462 hasConcept C2780580376 @default.
• W2006808462 hasConcept C2780852908 @default.
• W2006808462 hasConcept C29730261 @default.
• W2006808462 hasConcept C42219234 @default.
• W2006808462 hasConcept C71924100 @default.
• W2006808462 hasConcept C90924648 @default.
• W2006808462 hasConceptScore W2006808462C112705442 @default.
• W2006808462 hasConceptScore W2006808462C121608353 @default.
• W2006808462 hasConceptScore W2006808462C126322002 @default.
• W2006808462 hasConceptScore W2006808462C2780580376 @default.
• W2006808462 hasConceptScore W2006808462C2780852908 @default.
• W2006808462 hasConceptScore W2006808462C29730261 @default.
• W2006808462 hasConceptScore W2006808462C42219234 @default.
• W2006808462 hasConceptScore W2006808462C71924100 @default.
• W2006808462 hasConceptScore W2006808462C90924648 @default.
• W2006808462 hasIssue "3" @default.
• W2006808462 hasLocation W20068084621 @default.
• W2006808462 hasLocation W20068084622 @default.
• W2006808462 hasOpenAccess W2006808462 @default.
• W2006808462 hasPrimaryLocation W20068084621 @default.
• W2006808462 hasRelatedWork W148728087 @default.
• W2006808462 hasRelatedWork W1979418062 @default.
• W2006808462 hasRelatedWork W2005374976 @default.
• W2006808462 hasRelatedWork W2030053732 @default.
• W2006808462 hasRelatedWork W2033508602 @default.

• next